资源描述:
《TF方案和FOLFOX6方案治疗晚期胃癌的临床观察》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、-新疆医科大学硕士学位论文TF方案和FOLFOX6方案治疗晚期胃癌的临床观察研究生:彭媛媛导师:唐勇副教授摘要目的:比较TF方案和FOLFOX6方案治疗晚期胃癌的疗效及不良反应。方法:回顾性分析我院54例经病理确诊的晚期胃癌患者。A组28例,采用TF化疗方案:多西他赛50mg/m2,d1;CF400mg/m2,d1;5-FU40mg/m2,d1,5-FU2400~3000mg/m2,CⅣ(46小时),每14天为一周期,B组26例,采用FOLFOX6方案化疗:L-OHP100mg/m2,d1;CF400mg/m2,d1;5-FU400mg/m2,d1,
2、5-FU2400-3000mg/m2,CⅣ(46小时),每14天为一周期,对两组的近期疗效、生活质量改善情况、总生存期、无疾病进展时间、不良反应进行比较。结果:A组和B组的有效率分别为46.40%和46.20%,差异无统计学意义(P=0.99)。A组和B组的无疾病进展时间分别为5.5月,差异无统计学意义(P=0.54)。中位生存时间分别8.0月和8.5月,差异无统计学意义(P=0.71),A组和B组的生活质量改善为64.3%和30.80%差异有统计学意义(P=0.04);两组主要不良反应白细胞减少、血红蛋白减少、恶心、呕吐、便秘等指标的差异具有显著性
3、(P<0.05)。结论:TF方案和FOLFOX6方案在晚期胃癌的治疗方面近期疗效比较好,在不良反应以及生活质量改善情况等方面,TF方案优于FOLFOX6方案,具有更好的耐受性。关键词:晚期胃癌;化学治疗;TF方案;FOLFOX6方案;1---新疆医科大学硕士学位论文TFregimenandFOLFOX6regimenonadvancedgastriccarcinomainadvancedgastriccancerPostgraduate:PengYuanyuanSupervisor:AssociateProf.TangYongAbstractObje
4、ctive:TocomparetheefficacyandtoxicityofTFregimenandFOLFOX6regimenonadvancedgastriccarcinoma(AGG)ingastriccancer.Methods:Retrospectiveanalysisof54casesconfirmedbypathologyinpatientswithadvancedgastriccancer,28patientsingroupAtreatedwithDFregimen:Docetaxel50mg/m2,d1;CF400mg/m2,d1
5、;5-FU400mg/m2,d1;5-FU2400~3000mg/m2,CⅣ(46h),weregiven,repeatedevery14days;26patientsingroupBtreatedwithFOLFOX6regimen:L-OHP100mg/m2,d1;CF400mg/m2,d1;5-FU400mg/m2,d1;5-FU2400~3000mg/m2,CⅣ(46h),weregiven,repeatedevery14days.Theefficacy,ProgressionFreeSurvival(PFS),overallsurvival
6、(OS),improvementofQOLandtoxicityofthetworegimenswereanalyzed.Results:Theresponserate(RR)ofgroupAandBwere46.40%and46.20%,Differencewasstatisticallysignificant(P=0.99).ThemedianPFSwas5.50monthsingroupAand5.50monthsingroupB(P=0.54).Themediansurvivaltimewas8.00monthsingroupAand8.50
7、monthsingroupB,Differencewasstatisticallysignificant(P=0.71).TheimprovementrateofQOLofAandBwere64.30%and30.80%,Differencewasstatisticallysignificant(P=0.04).Majorsideeffectofthetwogroupshadsignificantdeference(P<0.05).Conclusion:BothTFandFOLFOX6regimenswereeffectiveintreatingad
8、vancedgastriccancerinpatients.TFregimenisbetterthanFOL